Challenges for Clinical Drug Development in Pulmonary Fibrosis
Pulmonary fibrosis is a pathologic process associated with scarring of the lung interstitium. Interstitial lung diseases (ILDs) encompass a large and heterogenous group of disorders, a number of which are characterized by progressive pulmonary fibrosis that leads to respiratory failure and death. Id...
Saved in:
Main Authors: | Eric S. White (Author), Matthew Thomas (Author), Susanne Stowasser (Author), Kay Tetzlaff (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Parametric Time‐to‐Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis
by: Fei Tang, et al.
Published: (2020) -
Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
by: Bonella F, et al.
Published: (2015) -
Estimating trends in working life expectancy based on health insurance data from Germany - Challenges and advantages
by: J. Tetzlaff, et al.
Published: (2022) -
Plain language summary: clinical trial of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
by: Luca Richeldi, et al.
Published: (2022) -
Healthy enough to work up to age 67 and beyond? A longitudinal population-based study on time trends in working life expectancy free of cardiovascular diseases based on German health insurance data
by: Fabian Tetzlaff, et al.
Published: (2024)